Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CIRRH
MCID: LVR012
MIFTS: 66

Liver Cirrhosis (CIRRH)

Categories: Endocrine diseases, Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Cirrhosis

About this section

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 38 12 76 29 55 6 44 15 73
Cirrhosis 12 75 55 43 15 40 73
Cirrhosis, Cryptogenic 73
Cryptogenic Cirrhosis 75
Cirrhosis of Liver 12
Cirrh 75

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5082
ICD10 33 K74.60
MeSH 44 D008103
NCIt 50 C2951
SNOMED-CT 68 19943007
Sources

Summaries for Liver Cirrhosis

About this section
MedlinePlus : 43 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and cryptogenic cirrhosis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is KRT8 (Keratin 8), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and FOXA2 and FOXA3 transcription factor networks. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood, and related phenotype is liver/biliary system.

Wikipedia : 76 Cirrhosis is a condition in which the liver does not function properly due to long-term damage. This... more...

Sources

Related Diseases for Liver Cirrhosis

About this section

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 867)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 34.2 AFP ALB F2 SLC17A5 TF
2 cryptogenic cirrhosis 31.7 F2 HFE KRT18 KRT8
3 hepatitis b 31.5 AFP ALB F2 GPT SLC17A5
4 portal hypertension 31.5 ALB F2 GPT
5 hepatitis 31.4 AFP F2 GPT KRT18 KRT8 SLC17A5
6 esophageal varix 31.4 AFP ALB F2 SERPINC1
7 hepatoportal sclerosis 31.3 F2 GPT
8 portal vein thrombosis 31.3 AFP F2 SERPINC1
9 hepatic encephalopathy 31.3 ALB F2 GPT SLC17A5
10 hepatic coma 31.2 ALB F2 GPT
11 hypersplenism 31.1 ALB F2 SERPINC1
12 hepatorenal syndrome 30.9 ALB F2 REN
13 hemosiderosis 30.8 GPT HFE TF
14 infantile liver failure syndrome 1 30.8 ALB F2 GPT SLC17A5
15 alcohol abuse 30.6 GPT SLC17A5 TF
16 alpha-1-antitrypsin deficiency 30.6 ALB HFE SERPINA1 SERPINC1
17 protein-energy malnutrition 30.6 ALB GPT TF
18 autoimmune hepatitis 30.5 F2 GPT KRT8
19 cholangitis 30.5 ALB F2 GPT
20 arteries, anomalies of 30.5 ALB REN SERPINC1
21 endocarditis 30.4 ALB F2 SERPINC1
22 choledocholithiasis 30.4 ALB F2 GPT SLC17A5
23 obstructive jaundice 30.3 ALB F2 GPT HGF REN SLC17A5
24 abdominal tuberculosis 30.3 ALB F2
25 viral hepatitis 30.2 AFP ALB F2 GPT HFE KRT18
26 siderosis 30.2 HFE SERPINA1 TF
27 hepatocellular carcinoma 30.1 AFP ALB F2 GAS5 HFE HGF
28 antipyrine metabolism 30.1 ALB F2
29 liver disease 30.1 AFP ALB F2 GPT HFE HGF
30 dysfibrinogenemia 30.1 ALB F2 SERPINC1
31 hepatitis e 30.1 ALB F2 GPT
32 pulmonary embolism 30.0 ALB F2 SERPINC1
33 bilirubin metabolic disorder 30.0 ALB F2 GPT SLC17A5
34 biliary atresia 30.0 ALB GPT HGF
35 hepatitis a 30.0 AFP ALB F2 GPT
36 fascioliasis 30.0 ALB GPT SLC17A5
37 kwashiorkor 30.0 ALB F2 GPT SLC17A5 TF
38 analbuminemia 30.0 ALB F2 GPT SLC17A5 TF
39 acute liver failure 30.0 ALB F2 GPT HGF SLC17A5
40 alcoholic hepatitis 30.0 ALB F2 GPT KRT18 SLC17A5
41 congenital hepatic fibrosis 30.0 REN SLC17A5
42 wilson disease 30.0 ALB F2 GPT HFE TF
43 homocysteinemia 30.0 ALB F2 SERPINC1
44 nonalcoholic steatohepatitis 29.9 F2 GPT HFE KRT18 SLC17A5
45 constrictive pericarditis 29.9 ALB SERPINA1
46 fatty liver disease, nonalcoholic 1 29.8 GPT KRT18 SLC17A5
47 cholecystitis 29.8 ALB F2 GPT KRT18
48 pyridoxine deficiency 29.7 GPT SLC17A5
49 vascular disease 29.7 ALB F2 REN SERPINC1
50 peripheral vascular disease 29.7 ALB F2 SERPINC1

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis
Sources

Symptoms & Phenotypes for Liver Cirrhosis

About this section

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Liver Cirrhosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 AFP ALB HFE HGF KRT18 KRT8
Sources

Drugs & Therapeutics for Liver Cirrhosis

About this section

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 747)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
3
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
5
Magnesium oxide Approved Phase 4 1309-48-4 14792
6
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
7
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Early Phase 1,Not Applicable 85721-33-1 2764
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
11
Cefoxitin Approved Phase 4 35607-66-0 441199
12
Imipenem Approved Phase 4,Not Applicable 74431-23-5, 64221-86-9 104838
13
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
15
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
16
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
17
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
18
Entecavir Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142217-69-4 153941
19
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
20
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833
21
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
22
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
23
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
24
Insulin glulisine Approved Phase 4 207748-29-6
25
Insulin Glargine Approved Phase 4 160337-95-1
26
Lactulose Approved Phase 4,Phase 2,Phase 3,Not Applicable 4618-18-2 11333
27
acetic acid Approved Phase 4 64-19-7 176
28 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
29
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
31
Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
32
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
34
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
35
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
36
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
37
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
38
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
39
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
40
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
41
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
42
Lypressin Approved Phase 4,Phase 2,Phase 3,Not Applicable 50-57-7
43
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 14636-12-5 72081
44
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
45
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
46
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
47
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
48
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 38904 498142
49
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
50
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 1984)
# Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4 losartan (drug)
5 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
6 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
7 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
8 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
9 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
10 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
11 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
12 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
13 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
14 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
15 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
16 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
17 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
18 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
19 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
20 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
21 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
22 The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices Unknown status NCT02638415 Phase 4 Carvedilol
23 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
24 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Unknown status NCT02695732 Phase 4 Carvedilol
25 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
26 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
27 The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
28 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
29 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
30 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4 propranolol
31 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
32 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
33 Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
34 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
35 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
36 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
37 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
38 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
39 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
40 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
41 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
42 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
43 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
44 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
45 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
46 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
47 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
48 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
49 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
50 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC�, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21771778 22121493
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel�) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Sources

Genetic Tests for Liver Cirrhosis

About this section

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Liver Cirrhosis 29
Sources

Anatomical Context for Liver Cirrhosis

About this section

MalaCards organs/tissues related to Liver Cirrhosis:

41
Liver, Bone, Testes, Kidney, Spleen, Bone Marrow, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Liver Cirrhosis

About this section

Articles related to Liver Cirrhosis:

(show top 50) (show all 3278)
# Title Authors Year
1
Mortality from liver angiosarcoma, hepatocellular carcinoma, and cirrhosis among vinyl chloride workers. ( 30474170 )
2019
2
Late onset cardiac cirrhosis and portal hypertensive ascites after atrial fibrillation ablation. ( 30419795 )
2019
3
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy. ( 30392460 )
2019
4
Serum miR-21 and miR-26a Levels Negatively Correlate with Severity of Cirrhosis in Patients with Chronic Hepatitis B. ( 30147020 )
2019
5
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. ( 30247174 )
2019
6
Prevalence and characteristics of hepatopulmonary syndrome in children with cirrhosis in southern Brazil. ( 30045096 )
2019
7
Hepatopulmonary syndrome-attributed extreme hypoxemia and polycythemia revealing liver cirrhosis. ( 30269997 )
2019
8
Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis. ( 30430787 )
2019
9
The association of bile acids and adrenomedullin, which can lead to hyperdynamic circulation in cirrhosis. ( 30507641 )
2019
10
Alcohol-Associated Cirrhosis. ( 30454826 )
2019
11
Dietary Interventions in Liver Cirrhosis. ( 29912757 )
2018
12
The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis. ( 29520208 )
2018
13
Diagnostic and Prognostic Role of Serum Interleukin-6 in Malignant Transformation of Liver Cirrhosis. ( 29963457 )
2018
14
Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the PortalA Vein. ( 29351835 )
2018
15
Circulating Endothelial Progenitor Cells Present an Inflammatory Phenotype and Function in Patients With Alcoholic Liver Cirrhosis. ( 29872403 )
2018
16
Managing portal hypertension in patients with liver cirrhosis. ( 29780579 )
2018
17
The protective effect of pentoxifylline versus silymarin on the pancreas through increasing adenosine by CD39 in a rat model of liver cirrhosis: Pharmacological, biochemical and histological study. ( 29408309 )
2018
18
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
19
Doppler assessment of children with liver cirrhosis and portal hypertension in comparison with a healthy control group: An analytical cross-sectional study. ( 29937902 )
2018
20
Changing Etiology in Liver Cirrhosis in Sapporo, Japan. ( 29963470 )
2018
21
Platelet Count and Prediction of Bleeding in Patients With Liver Cirrhosis. ( 29895981 )
2018
22
Importance of the Average Glucose Level and Estimated Glycated Hemoglobin in a Diabetic Patient with Hereditary Hemolytic Anemia and Liver Cirrhosis. ( 29225250 )
2018
23
Number of hospital contacts with alcohol problems predicts later risk of alcoholic liver cirrhosis. ( 29528775 )
2018
24
Severe hyponatremia after direct-acting antiviral treatment in a patient with virus C compensated liver cirrhosis and kidney transplant. ( 29922767 )
2018
25
Leukemic mature B-cell neoplasm observed during the treatment with romiplostim in patient with thrombocytopenia and liver cirrhosis. ( 29881570 )
2018
26
Refractory Ascites in Liver Cirrhosis. ( 29973706 )
2018
27
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
28
Evaluation of Hepatoprotective Effect of Curcumin on Liver Cirrhosis Using a Combination of Biochemical Analysis and Magnetic Resonance-Based Electrical Conductivity Imaging. ( 29887757 )
2018
29
Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis. ( 29897895 )
2018
30
VALIDATION OF CLIF-C-ACLF SCORE FOR ALCOHOLIC LIVER CIRRHOSIS. ( 29905553 )
2018
31
Use of indocyanine green dye clearance in a patient with liver cirrhosis undergoing hepatectomy: a clinical image. ( 29950373 )
2018
32
Estimation of hepatic fat fraction using modified Dixon magnetic resonance imaging techniques: effect of liver cirrhosis. ( 29448119 )
2018
33
Efficacy and safety of endoscopic submucosal dissection for gastric neoplasms in patients with compensated liver cirrhosis: a propensity score-matched case-control study. ( 29410022 )
2018
34
Genetic polymorphisms in ataxin-3 and liver cirrhosis risk related to aflatoxin B1. ( 29937988 )
2018
35
MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. ( 29416678 )
2018
36
Ratio of mean platelet volume to platelet count is a potential surrogate marker predicting liver cirrhosis. ( 29399281 )
2018
37
Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. ( 29405667 )
2018
38
Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedurea88- A Nationwide Survey in Japan. ( 29445059 )
2018
39
Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection. ( 29423099 )
2018
40
Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. ( 29407630 )
2018
41
Large-volume paracentesis effects plasma disappearance rate of indo-cyanine green in critically ill patients with decompensated liver cirrhosis and intraabdominal hypertension. ( 29980962 )
2018
42
Transient portal vein thrombosis in liver cirrhosis. ( 29871683 )
2018
43
Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. ( 29438135 )
2018
44
Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis. ( 29435187 )
2018
45
Gallbladder perforation in a patient with alcoholic liver cirrhosis and asymptomatic gallstones: A case report. ( 29718836 )
2018
46
The association between liver cirrhosis and fracture risk: a systematic review and meta-analysis. ( 29885255 )
2018
47
Effects of liver cirrhosis on portal vein embolization prior to right hepatectomy in patients with primary liver cancer. ( 29434832 )
2018
48
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
49
Discriminatory CT-textural features in splenic infiltration of lymphoma versus splenomegaly in liver cirrhosis versus normal spleens in controls and evaluation of their role for longitudinal lymphoma monitoring. ( 29857858 )
2018
50
Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. ( 29753054 )
2018
Sources

Variations for Liver Cirrhosis

About this section

ClinVar genetic disease variations for Liver Cirrhosis:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRT18 NM_000224.2(KRT18): c.383A> T (p.His128Leu) single nucleotide variant Pathogenic,risk factor rs57758506 GRCh37 Chromosome 12, 53343340: 53343340
2 KRT18 NM_000224.2(KRT18): c.383A> T (p.His128Leu) single nucleotide variant Pathogenic,risk factor rs57758506 GRCh38 Chromosome 12, 52949556: 52949556
3 KRT8 NM_002273.3(KRT8): c.184G> T (p.Gly62Cys) single nucleotide variant Pathogenic,risk factor rs11554495 GRCh37 Chromosome 12, 53298582: 53298582
4 KRT8 NM_002273.3(KRT8): c.184G> T (p.Gly62Cys) single nucleotide variant Pathogenic,risk factor rs11554495 GRCh38 Chromosome 12, 52904798: 52904798
5 KRT8 NM_002273.3(KRT8): c.160T> C (p.Tyr54His) single nucleotide variant Pathogenic rs57749775 GRCh37 Chromosome 12, 53298606: 53298606
6 KRT8 NM_002273.3(KRT8): c.160T> C (p.Tyr54His) single nucleotide variant Pathogenic rs57749775 GRCh38 Chromosome 12, 52904822: 52904822
7 FARSB NM_005687.4(FARSB): c.1381A> C (p.Thr461Pro) single nucleotide variant Pathogenic GRCh38 Chromosome 2, 222613892: 222613892
8 FARSB NM_005687.4(FARSB): c.1381A> C (p.Thr461Pro) single nucleotide variant Pathogenic GRCh37 Chromosome 2, 223478611: 223478611
9 FARSB NM_005687.4(FARSB): c.784A> G (p.Lys262Glu) single nucleotide variant Pathogenic GRCh37 Chromosome 2, 223496325: 223496325
10 FARSB NM_005687.4(FARSB): c.784A> G (p.Lys262Glu) single nucleotide variant Pathogenic GRCh38 Chromosome 2, 222631606: 222631606
11 FARSB NM_005687.4(FARSB): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic GRCh37 Chromosome 2, 223488418: 223488418
12 FARSB NM_005687.4(FARSB): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic GRCh38 Chromosome 2, 222623699: 222623699
13 FARSB NM_005687.4(FARSB): c.755T> C (p.Phe252Ser) single nucleotide variant Pathogenic GRCh38 Chromosome 2, 222631635: 222631635
14 FARSB NM_005687.4(FARSB): c.755T> C (p.Phe252Ser) single nucleotide variant Pathogenic GRCh37 Chromosome 2, 223496354: 223496354
15 FARSB NM_005687.4(FARSB): c.226T> C (p.Cys76Arg) single nucleotide variant Pathogenic GRCh38 Chromosome 2, 222642894: 222642894
16 FARSB NM_005687.4(FARSB): c.226T> C (p.Cys76Arg) single nucleotide variant Pathogenic GRCh37 Chromosome 2, 223507613: 223507613

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis
Sources

Expression for Liver Cirrhosis

About this section
Search GEO for disease gene expression data for Liver Cirrhosis.
Sources

Pathways for Liver Cirrhosis

About this section

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.05 AFP ALB HGF SERPINA1
2
FOXA2 and FOXA3 transcription factor networks 1
10.78 AFP ALB F2
3
LncRNA-mediated mechanisms of therapeutic resistance 1
10.23 HOTAIR MEG3